ION 260
Alternative Names: BIIB-132; ION-260Latest Information Update: 21 Feb 2024
At a glance
- Originator Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Ataxin 3 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Machado-Joseph Disease
Most Recent Events
- 21 Feb 2024 Discontinued - Phase-I for Machado-Joseph Disease (In the elderly, In adults) in Israel, Netherlands, Portugal, United Kingdom, Germany, USA (Intrathecal) (Ionis Pharmaceuticals pipeline, February 2024)
- 25 Jul 2023 Biogen terminates a phase-I trial in Machado-Joseph Disease (In the elderly, In adults) in USA, United Kingdom, Portugal, Netherlands, Israel, Germany (Intrathecal) (NCT05160558)
- 02 Feb 2022 Phase-I clinical trials in Machado-Joseph Disease (In adults, In the elderly) in USA (Intrathecal) (NCT05160558) (EudraCT2021-002223-37)